Trial Outcomes & Findings for Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens (NCT NCT00762021)

NCT ID: NCT00762021

Last Updated: 2010-12-22

Results Overview

Thickening and opacification of the transparent membrane on which the intraocular lens is placed assessed by taking a digital retroillumination image of each eye with a dedicated retroillumination camera system. The photographs were analyzed with POCO software to measure the percentage area of PCO in the capsulorhexis area.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

104 participants

Primary outcome timeframe

2 years after surgery

Results posted on

2010-12-22

Participant Flow

Uncomplicated age-related bilateral cataract with the potential to see 20/40 or better in each eye

During the preoperative exam, subjects were examined to ensure they met the inclusion/exclusion criteria.

Participant milestones

Participant milestones
Measure
SN60AT
Implantation with the AcrySof Intraocular Lens Model SN60AT
SN60WF
Implantation with the AcrySof Intraocular Lens Model SN60WF
Overall Study
STARTED
52
52
Overall Study
COMPLETED
44
44
Overall Study
NOT COMPLETED
8
8

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
SN60AT
n=52 Participants
Implantation with the AcrySof Intraocular Lens Model SN60AT
SN60WF
n=52 Participants
Implantation with the AcrySof Intraocular Lens Model SN60WF
Total
n=104 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
12 Participants
n=5 Participants
12 Participants
n=7 Participants
24 Participants
n=5 Participants
Age, Categorical
>=65 years
40 Participants
n=5 Participants
40 Participants
n=7 Participants
80 Participants
n=5 Participants
Sex: Female, Male
Female
29 Participants
n=5 Participants
29 Participants
n=7 Participants
58 Participants
n=5 Participants
Sex: Female, Male
Male
23 Participants
n=5 Participants
23 Participants
n=7 Participants
46 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 2 years after surgery

Population: Data for all patients completing the 24 month visit were analyzed.

Thickening and opacification of the transparent membrane on which the intraocular lens is placed assessed by taking a digital retroillumination image of each eye with a dedicated retroillumination camera system. The photographs were analyzed with POCO software to measure the percentage area of PCO in the capsulorhexis area.

Outcome measures

Outcome measures
Measure
SN60AT
n=40 Participants
Implantation with the AcrySof Intraocular Lens Model SN60AT
SN60WF
n=40 Participants
Implantation with the AcrySof Intraocular Lens Model SN60WF
Posterior Capsule Opacification (PCO)
11.58 Percentage of PCO
Standard Deviation 20.18 • Interval 9.53 to 31.75
14.04 Percentage of PCO
Standard Deviation 22.15 • Interval 11.79 to 36.19

PRIMARY outcome

Timeframe: 24 months after surgery

Population: Data for all patients completing the 24 month visit were analyzed.

Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under high contrast (100%), which means that there was maximum contrast between the letters on the chart and the background. VA is measured in logMAR. LogMAR is the "logarithm of the minimum angle of resolution". A lower logMAR value indicates better visual acuity.

Outcome measures

Outcome measures
Measure
SN60AT
n=40 Participants
Implantation with the AcrySof Intraocular Lens Model SN60AT
SN60WF
n=40 Participants
Implantation with the AcrySof Intraocular Lens Model SN60WF
100% LogMAR Best Corrected Visual Acuity (BCVA)
0.04 LogMAR
Standard Deviation 0.1 • Interval 0.0 to 0.08
0.07 LogMAR
Standard Deviation 0.2 • Interval -0.02 to 0.04

PRIMARY outcome

Timeframe: 24 months after surgery

Population: Data for all patients completing the 24 month visit were analyzed.

Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under low contrast (9%), which means that there was low contrast between the letters on the chart and the background. VA is measured in logMAR. LogMAR is the "logarithm of the minimum angle of resolution". A lower logMAR value indicates better visual acuity.

Outcome measures

Outcome measures
Measure
SN60AT
n=40 Participants
Implantation with the AcrySof Intraocular Lens Model SN60AT
SN60WF
n=40 Participants
Implantation with the AcrySof Intraocular Lens Model SN60WF
9% LogMAR Best Corrected Visual Acuity (BCVA)
0.42 LogMAR
Standard Deviation 0.2 • Interval 0.36 to 0.48
0.45 LogMAR
Standard Deviation 0.2 • Interval 0.29 to 0.37

Adverse Events

SN60AT

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

SN60WF

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Alcon Clinical

Alcon Research, Ltd.

Phone: 888.451.3937; 817.568.6725

Results disclosure agreements

  • Principal investigator is a sponsor employee Publications relating to the study should not be made without the Sponsor's prior written consent and not prior to the completion of the study. The sponsor shall be notified in writing at least 60 days prior to submission of any intention on the part of the Investigator to publish and shall provide the sponsor an opportunity to comment on any proposed publications.
  • Publication restrictions are in place

Restriction type: OTHER